QualityDipStocks / Health Care · Pharmaceuticals
Takeda Pharmaceutical Company TAK
Outside our quality screen, so we don’t track its dips. It’s at its 52-week high.
Outside our quality screen. No fair value estimate for now: its filings are too old.
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- at the high
- Risk vs market
- Lowbeta 0.07
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $20.91
- 52-wk lowlowest close, 1 year$13.23−36.7%
- 52-wk highhighest close, 1 year$20.91at the price
- PriceFri Oct 30 close$20.91you are here
Fair value estimate
No estimate for TAK: Latest cash-flow data in SEC XBRL ends 2025-03-31, too old to use. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much TAK moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 1.7× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.07
- Volatility
- 22% vs 13% SPY
- Correlation SPY
- 0.04
- Correlation QQQ
- −0.13
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ValuationFree-cash-flow yield of 8.7% (price / FCF 11.5×): $5.5B of free cash in the last 12 months.
Cash returnsDividend yield of 3.1% ($2.0B paid over 12 months).
Balance sheetNet cash of $526M: cash and short-term investments exceed debt (Mar 31, 2026).
Balance sheetDebt / equity of 0.1×, below the 0.7× median for the 67 Health Care companies we cover.
Top bearish points 5 of 5
Balance sheetOperating income covers interest only 0.0× over the last 12 months.
ProfitabilityLost $967M over the last 12 months (net income, SEC filings).
Balance sheetDebt rose 39% to $3.2B from FY2024 to FY2026.
ProfitabilityOperating margin narrowed to 0.1% in FY2026 from 5.0% in FY2024 (SEC filings).
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; net debt 5.4× EBITDA (limit 3×).
Who’s talking about it
Notable investors, executives, analysts and public figures on Takeda Pharmaceutical Company in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
All fundamentals
FCF yield 8.7% · ROE -2% · Sales −2%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- 11.5×
- FCF yield
- 8.7%
- EV / EBITDA
- 13.6×
- Price / sales
- 2.21×
- Price / book
- 1.34×
- Market cap
- $63.2Blisted
- Enterprise value
- $62.7B
Growth
- Revenue, 12 months
- $28.6B
- Sales growth, 12 months
- −1.7%vs the 12 months before
- Sales growth, 3 yrs
- +3.8%/yrfrom FY2023
- Diluted EPS, 12 months
- −$96.75
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$967M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 65.1%
- Operating margin
- 0.1%
- Net margin
- −3.4%
- FCF margin
- 19.2%
- Return on equity
- −2%
- Return on invested capital
- 0%
Balance sheet
- Cash & short-term inv.
- $3.8B
- Total debt
- $3.2B
- Net cash
- $526M
- Debt / equity
- 0.07×
- Interest coverage
- 0.0×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $5.5B
- FCF growth, 12 months
- +1%
- Dividend yield
- 3.13%$2.0B paid
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $327M0.5% of market cap
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Mar 31, 2026; balance sheet at Mar 31, 2026. From Takeda Pharmaceutical Company’s SEC filings, reported in JPY and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
FCF value $3,589
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 72 · 5 days +3.3%
The business
FCF $433.9B · Sales +7%
- Free cash flow, 12 months$433.9B
- Free-cash-flow yield686.6%
- Free-cash-flow margin9%
- Gross margin66%
- Operating margin14%
- Return on invested capital4%
- Return on equity0%
- Sales growth (latest quarter vs year-ago quarter)+7%
- Net debt / EBITDA5.4×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
TAK is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.